A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Phase 2 Active not recruiting 182 enrolled Mirum Pharmaceuticals, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.

Timeline

Start: 2020-12-18
Primary completion: 2026-06
Completion: 2027-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Volixibat	Small molecule	20 mg	Oral
Subject	Volixibat	Small molecule	80 mg	Oral

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Summary

Timeline

Drugs

Indications